11 Matching Annotations
  1. May 2020
  2. Feb 2020
    1. Secondary care treatment options include plasma-derived C1 esterase inhibitor (C1-INH) concentrates, ecallantide (a kallikrein inhibitor [kallikrein is involved in the production of bradykinin]), icatibant (a bradykinin receptor antagonist), prophylactic doses of C1-INH, and long-term prophylaxis with danazol (an androgen)

      Treatment of HAE and AAE - do not respond to antihistamines

      • plasma-derived C1 esterase inhibitor (C1-INH) concentrates
      • ecallantide (a kallikrein inhibitor [kallikrein is involved in the production of bradykinin]),
      • icatibant (a bradykinin receptor antagonist)
      • prophylactic doses of C1-INH
      • long-term prophylaxis with danazol (an androgen)
    2. Offer a non-sedating antihistamine (such as cetirizine, fexofenadine, or loratadine) for up to 6 weeks (use clinical judgement to determine the duration of treatment). 

      Treatment of angio-oedema

      • Stop ACEI
      • Non-sedating antihistamine 6 weeks (can give up to 4x standard max dose)
      • Short-course of oral corticosteroid if severe
      • Specialist opinion on continuing beta blockers
  3. Nov 2019
  4. Sep 2019
  5. May 2019
  6. Jul 2018